News | Artificial Heart | May 27, 2020

First Implantation of Carmat Total Artificial Heart in Denmark

This implant, performed at Rigshospitalet in Copenhagen, marks the resumption of the recruitment in the PIVOTAL study and brings the total number of patients to 13

May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first implantation of its bioprosthetic artificial heart in Denmark. The company aims to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure.

The implant procedure was performed by the team of Dr. Peter Skov Olsen, cardiothoracic surgeon at the Heart Center of Rigshospitalet in Copenhagen. It is the first Danish hospital to implant the Carmat total artificial heart and the third international medical center contributing to the PIVOTAL study, together with the Institute for Clinical and Experimental Medicine (IKEM) in Prague, Czech Republic, and the National Research Center for Cardiac Surgery in Nur-Sultan, Kazakhstan.

Finn Gustafsson, M.D., Ph.D., professor of advanced heart failure and transplantation at the Heart Center and principal investigator of the study, comments: "We are excited to gain clinical experience with the Carmat total artificial heart (TAH) and to contribute to the PIVOTAL study. With its hemocompatibility, autoregulation and silent operation, the Cartmat TAH could become a real alternative treatment to heart transplantation for patients suffering from end-stage heart-failure."

"Rigshospitalet has developed a strong expertise in treating advanced heart failure and has participated in front-line clinical studies with innovative medical therapies and devices in this field," said Stéphane Piat, CEO of Carmat. "I am delighted that such an internationally recognized site becomes the third international center to implant our device. With the recent release of certain COVID-19 pandemic-related restrictions, Carmat's teams and proctors were able to prepare and participate in the surgical procedure and early post-operative follow up. To date, 13 patients have received our device in the PIVOTAL study and, subject to the progressive ramp-up in recruitments across our three active study centers, we estimate that 4-5 months are needed to complete enrollment and reach the total of 20 patients."

In accordance with good clinical practice and subject to regulatory obligations or specific circumstances, Carmat will not provide individual updates on patients' implantations or their health condition. However, it is planning to communicate when major milestones in the PIVOTAL study are reached, such as the opening of new centers and the overall progression of patient recruitment.


Related Carmat Artificial Heart Content:

Carmat to initiate FDA U.S. Feasibility Study of Total Artificial Heart

Carmat Announces Start of the PIVOTAL Study

VADs Gaining Popularity, But Artificial Hearts Remain the Ideal, Says GlobalData Analyst

Related Content

The Carmat system, an experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can adjust to the changing needs of patients treated for end-stage heart failure. Outcomes in the first series of patients managed with the new heart replacement pump in Auto-Mode are presented in the journal of the American Society for Artificial Internal Organs (ASAIO). 

The Carmat artificial heart technology.

News | Artificial Heart | June 23, 2021
June 18, 2021 – An experimental artif...
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart | December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
CorInnova Awarded Seminal Patent for Minimally Invasively-Delivered Soft Robotic Heart Device
News | Artificial Heart | October 27, 2017
CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property...
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart | September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart | September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times
News | Artificial Heart | March 24, 2016
March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and
Bryan Tyo, Baylor University Medical Center, bridge to transplant, Total Artificial Heart
News | Artificial Heart | March 18, 2016
A surgical team at Baylor University Medical Center at Dallas successfully performed a heart transplant on a patient...